No announcement yet.

Neurology Generalized Myoclonus in COVID-19

  • Filter
  • Time
  • Show
Clear All
new posts

  • Neurology Generalized Myoclonus in COVID-19


    . 2020 May 21;10.1212/WNL.0000000000009829.
    doi: 10.1212/WNL.0000000000009829. Online ahead of print.
    Generalized Myoclonus in COVID-19

    Pablo Rábano-Suárez 1 , Laura Bermejo-Guerrero 1 , Antonio Méndez-Guerrero 1 , Javier Parra-Serrano 1 , Daniel Toledo-Alfocea 1 , Daniel Sánchez-Tejerina 1 , Teresa Santos-Fernández 1 , María Dolores Folgueira-López 2 3 , Judit Gutiérrez-Gutiérrez 4 , Blanca Ayuso-García 5 , Jesús González de la Aleja 1 , Julián Benito-León 6 1 1



    Objective: To report 3 patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) who developed generalized myoclonus.
    Methods: Patient data were obtained from medical records from the University Hospital "12 de Octubre," Madrid, Spain.
    Results: Three patients (2 men, and one woman, aged 63-88) presented with mild hypersomnia and generalized myoclonus following the onset of the so-called "inflammatory" phase of coronavirus disease 2019 (COVID-19). All of them had presented previously with anosmia. Myoclonus had a stereotypical pattern, being both positive and negative, generalized, with a predominant involvement of nasopharyngeal, facial, and upper limbs areas. These jerky movements occurred spontaneously and were extremely sensitive to multisensory stimuli (auditive and tactile) or voluntary movement, with an exaggerated startle response. Other causes of myoclonus were ruled-out, and none of them had undergone respiratory arrest or significant prolonged hypoxia. All of them improved, at least partially, with immunotherapy.
    Conclusions: Our 3 cases highlight the occurrence of myoclonus during the COVID-19 pandemic as a postinfectious/immune-mediated disorder. However, we cannot rule out that SARS-CoV-2 may spread transneuronally to first- and second-order structures connected with the olfactory bulb. Further investigation is required to clarify the full clinical spectrum of neurologic symptoms and its optimal treatment.

    © 2020 American Academy of Neurology.